Cochrane · systematic review · CD013024
Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
Threapleton, CJD, Janjua, S, Fortescue, R, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
7
No studies
4
Included studies
NR
No studies 4 · 28.6%Ungraded 3 · 21.4%Very low 4 · 28.6%Low 3 · 21.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Macrolide+tetracycline versus macrolide
Population: chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) Macrolide+tetracycline vs macrolide | no estimate extracted | 1 study · 187 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
All‐cause serious adverse events 60 weeks (end of study) Macrolide+tetracycline vs macrolide | OR 1 [0.52, 1.93] | 1 study · 198 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Lung function (trough FEV1) Change from baseline to 12 weeks (end of active treatment) Macrolide+tetracycline vs macrolide | no estimate extracted | 1 study · 182 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
All‐cause mortality 60 weeks (end of study) Macrolide+tetracycline vs macrolide | OR 1.63 [0.38, 7.02] | 1 study · 198 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa Macrolide+tetracycline vs macrolide | no estimate extracted | NR | No studies |
Quinolone versus tetracycline
Population: chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing one or more exacerbations Quinolone versus tetracycline Quinolone vs tetracycline | OR 0.44 [0.14, 1.38] | 1 study · 50 participants | Low Downgraded: imprecision |
All‐cause mortality Quinolone vs tetracycline | no estimate extracted | 1 study · 50 participants | Ungraded |
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa Quinolone vs tetracycline | no estimate extracted | NR | No studies |
Quinolone versus macrolide
Population: chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing one or more exacerbations Quinolone versus macrolide Quinolone vs macrolide | OR 1 [0.32, 3.1] | 1 study · 50 participants | Low Downgraded: imprecision |
All‐cause mortality Quinolone vs macrolide | no estimate extracted | 1 study · 50 participants | Ungraded |
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa Quinolone vs macrolide | no estimate extracted | NR | No studies |
Macrolide versus tetracycline
Population: chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing one or more exacerbations Macrolide versus tetracycline Macrolide vs tetracycline | OR 0.44 [0.14, 1.38] | 1 study · 50 participants | Low Downgraded: imprecision |
All‐cause mortality Macrolide vs tetracycline | no estimate extracted | 1 study · 50 participants | Ungraded |
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa Macrolide vs tetracycline | no estimate extracted | NR | No studies |